Live Cell Imaging Market worth $2.8 billion by 2025 – Exclusive Report by MarketsandMarkets – PRNewswire

CHICAGO, Oct. 29, 2020 /PRNewswire/ -- According to the new market research report "Live Cell Imaging Market by Product (Instruments, Consumables, Software, Services) Application (Cell Biology, Drug Discovery) Technology (Time-lapse Microscopy, FRET) End User (Contract Research Organization, Research Institutes) - Global Forecast to 2025", published by MarketsandMarkets, the global market size is projected to reach USD 2.8 billion by 2025 from USD 1.8 billion in 2020, at a CAGR of 8.8% during the forecast period.

Browse in-depth TOC on "Live Cell Imaging Market"

146 Tables 40 Figures 212 Pages

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=163914483

The growing adoption of high-content screening techniques in drug discovery, rising incidence of cancer, and the growth in funding for research are the major factors driving the growth of this market.

"The reagents segment is expected for the largest share of the live cell imaging market in 2019."

Based on type, the live cell imaging consumables market is segmented into reagents, media, assay kits, and other consumables (microplates, slides, Petri dishes, coverslips, and culture chambers). In 2019, the reagents segment accounted for the largest share of 36.1% of the consumables market. The large share of this segment can primarily be attributed to the growing applications of biosciences and biotechnology within the pharmaceutical and healthcare fields. With advancements in technologies, the demand for high-quality reagents in biomedical research and processing is on the rise. The increasing demand for high-quality reagents and their repeated use in live-cell imaging procedures are also factors driving the growth of this market.

By technology, the high-content screening (HCS) segment is expected to grow at the highest CAGR during the forecast period."

Based on technology, the live cell imaging market is segmented into fluorescence resonance energy transfer (FRET), time-lapse microscopy, fluorescence recovery after photobleaching (FRAP), high-content screening (HCS), and other technologies. High-content screening (HCS) segment is expected to grow at the highest CAGR during the forecast period. This growth can be attributed to the increasing studies on cell behavior and the need to correlate multiple events and markers with cell morphology.

Get 10% Customization on this Research Report: https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=163914483

"North America to hold the largest regional market share in 2019."

North America is expected to account for the largest share of the live cell imaging market in 2019, followed by Europe. The large share of North America can be attributed to factors such as the availability of government funding for life science research, drug development regulations, advances in live-cell imaging techniques, growth in the biotechnology and pharmaceutical industries, and the rising incidence of cancer.

The prominent players in this live cell imaging market are Danaher Corporation (US), Carl Zeiss AG (Germany), Nikon Corporation (Japan), Olympus Corporation (Japan), PerkinElmer, Inc. (US), GE Healthcare (US), Bruker Corporation (US), Thermo Fisher Scientific Inc. (US), Sartorius AG (Germany), Oxford Instruments (UK), BioTek Instruments (US), Etaluma, Inc. (US), CytoSMART Technologies (Netherlands), NanoEnTek Inc. (Korea), Phase Focus Limited (UK), Tomocube, Inc. (South Korea), Phase Holographic Imaging PHI AB (Sweden), BD Biosciences (US), Sony Biotechnology, Inc. (US), Merck KGaA (Germany), KEYENCE Corporation (Japan), ibidi GmbH (Germany), Bio-Rad Laboratories (US), Logos Biosystems (South Korea), and Nanolive SA (Switzerland).

Browse Adjacent Markets: Biotechnology Market ResearchReports & Consulting

Get Special Pricing on Bundle Reports: https://www.marketsandmarkets.com/RequestBundleReport.asp?id=163914483

Browse Related Reports:

Cell Culture Market by Product (Consumables (Media, FBS), Equipment (Bioreactor, Centrifuge, Incubator, Microscope, Autoclave)), Application (Stem Cell, Vaccines, Therapeutic proteins), End User (Pharma, Research Institutes) - Global Forecast to 2024

https://www.marketsandmarkets.com/Market-Reports/cell-culture-market-media-sera-reagents-559.html

Cell-based Assay Market by Product (Reagents, Microplates, Cell Lines, Assay Kits, Instruments, Services), Application (Drug Discovery, Research), End User (CROs, Biopharma Companies, Research Institutes), Geography - Global Forecast to 2024

https://www.marketsandmarkets.com/Market-Reports/cell-based-assays-market-119917269.html

About MarketsandMarkets

MarketsandMarkets provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:Mr. Aashish MehraMarketsandMarkets INC.630 Dundee RoadSuite 430Northbrook, IL 60062USA: +1-888-600-6441Email: [emailprotected] Research Insight: https://www.marketsandmarkets.com/ResearchInsight/live-cell-imaging-market.aspVisit Our Web Site: https://www.marketsandmarkets.comContent Source: https://www.marketsandmarkets.com/PressReleases/live-cell-imaging.asp

SOURCE MarketsandMarkets

See the article here:
Live Cell Imaging Market worth $2.8 billion by 2025 - Exclusive Report by MarketsandMarkets - PRNewswire

Role of Serotonin in The Developing Brain – BioTechniques.com

Researchers have identified a potential new role for the neurotransmitter serotonin that could explain a heretofore unknown evolutionary mystery.

Over the course of human evolution, the brain in particular the neocortex grew larger than our primate relatives, enabling us to think, speak and dream. The underlying mechanism of this neocortical expansion is unclear, with a number of potential molecular players having been identified. Each identified molecule is believed to act intrinsically in the basal progenitor cells of the developing neocortex, influencing its growth.

Now, researchers from the Max Planck Institute of Molecular Cell Biology and Genetics (Dresden, Germany) have identified serotonin as an additional player in this evolutionary expansion. In contrast to the previously identified molecules, serotonin is thought to act extrinsically to the progenitor cells, behaving as a growth factor in the developing brain.

Depression and anxiety: what is the scientific difference?

The biochemical differences between depression and anxiety have been elucidated, providing new insights for targeting treatment.

Placenta-derived serotonin reaches the brain via blood circulation and has been identified in both human and mice embryos, though its function in the developing brain remained a mystery. In the recent study, researchers identified the receptor HTR2A, which is found in human but not mice neocortices, leading the team to believe it may play a role in the development of the larger human brain. Indeed, when mice were genetically engineered to express the HTR2A receptor, they were found to develop much larger than normal neocortices.

We found that serotonin, by activating this receptor, caused a chain of reactions that resulted in the production of more basal progenitors in the developing brain. More basal progenitors can then increase the production of cortical neurons, which paves the way to a bigger brain, explained lead author Lei Xing.

Abnormal signaling of serotonin and a disturbed expression or mutation of its receptor HTR2A have been observed in various neurodevelopmental and psychiatric disorders, such as Down syndrome, attention deficit hyperactivity disorder and autism, commented research team leader Wieland Huttner. Our findings may help explain how malfunctions of serotonin and its receptor during fetal brain development can lead to congenital disorders and may suggest novel approaches for therapeutic avenues.

Follow this link:
Role of Serotonin in The Developing Brain - BioTechniques.com

bit.bio + London Institute for Mathematical Sciences = progress on industrial-scale production of all human cells – Cambridge Independent

A combination of mathematics and biology could enable industrial-scale production of all human cells for drug discovery or cell therapy - and accelerate the introduction of prototype organ printing.

That is the hope of cell coding company bit.bio, which has agreed a new partnership with the London Institute for Mathematical Sciences.

Helping to reduce reliance on animal testing, the organisations expect clinical trials of therapies based on bit.bios cells to be rolled out in three to five years.

Prototype organ printing could happen within 10 years, they hope.

Dr Mark Kotter, founder and CEO of bit.bio , said: Our collaboration with the London Institute is incredibly exciting, as we work on a paradigm shift in biology, moving it from an observational to a predictive science.

Over the past decade we have learned that biology can be viewed as a software. Our collaboration with LIMS will help to decode the operating system of life. This will unlock opportunities, including a new generation of cell therapies for tackling diseases such as cancer and dementia, accelerating drug development and could even help us combat pandemics of the future.

It has been a landmark year for bit.bio, which closed a $41.5million Series A investment in June , backed by former National Cancer Institute director Richard Klausner, among others.

The company, which also moved to new headquarters on Babraham Research Campus, has already created the first large-scale, high-purity batches of cells to test new Alzheimers and dementia drugs.

We are just at that critical time in biology where weve identified a huge bottleneck, which really consists of having access to a robust and scalable source of human cells, said Mark.

At bit.bio we combine data science and biology to make cells that nobody else can make.

The starting point for this is a platform technology that we call optio-x, which essentially allows us to execute genetic code in cells very robustly.

In order to be able to recreate every human cell, you need to create a model or an understanding of this operating system, which is our collaboration with LIMS.

Once youve got that you can also create a predictive model of a cell.

Mark sees biology increasingly moving towards engineering - a transition that has already taken place successfully in physics.

If you think about it, when Newton introduced calculus to physics, he gave us a tool to look into the future and in biology we are still at a point where we do experiments to generate data and we have very limited ways of predicting the outcome of an experiment.

If we had a better understanding of the control mechanisms of biology - I would say the software that runs in a human cell - then we would be able to also pivot biology into that new paradigm, he said.

Drugs tested on animals have a 97 per cent failure rate, partly due to differences between animal and human cells.

And progress on cell therapies for diseases such as cancer have been hampered by the lack of available human cells.

While synthetic biology has promised to overcome some of these challenges, it has been hindered by the difficulty in unlocking the fundamental laws governing cell identity.

But bit.bio has succeeded in creating high-purity batches of neurons, muscle cells and oligodendrocytes at scale and its patented technique holds the potential for the custom-building of any human cell.

With backing from Silicon Valley, and a scientific team including Dr Roger Pedersen, a pioneer of human stem cell biology and cell reprogramming expert Dr Marius Wernig, co-director of the Stanford Stem Cell Institute, it is poised to make a pioneering contribution.

The moonshot goal of bit.bio is to recreate every human cell in the body and then to provide them for research and drug discovery purposes, said Mark.

But at the same time there will be cell types that are going to be very valuable for therapeutic application in the form of cell therapies and perhaps in the future tissues or organs.

Bit.bios partnership with The London Institute for Mathematical Sciences, a private physics and maths research centre, aims to continue the fusion of biology and maths, so that all human cells can be read out and reprogrammed like software.

Dr Thomas Fink, founder and director of the London institute for Mathematical Sciences, said: Life is the final frontier of mathematics and the marriage of maths and biology will change the face of both disciplines.

Decoding cellular identity will require entirely new kinds of mathematics, as well as a deeper understanding of machine learning. Living organisms exhibit extraordinary concision and elegance, the hallmarks off mathematical structure.

The human genome amounts to just three gigabytes of data. But viruses, a mere seven kilobytes, can redirect it by calling up just the right subroutines, in a similar way to how modular software works. Uncovering the operating system of life could enable us to engineer human cells as readily as we do software.

Bit.bio is a nominee in the Cambridge Independent Science and Technology Awards. A shortlist will be announced in November, ahead of the winners being revealed early in 2021.

Read more

Beautiful science in operating system of life underpins $41.5m investment in bit.bio

Meet bit.bio as cell coding firm retires the Elpis Biomed name

Elpis BioMed: Mastering the art of reprogramming human cells

Read more from the original source:
bit.bio + London Institute for Mathematical Sciences = progress on industrial-scale production of all human cells - Cambridge Independent

2020 Dickson Prize in Medicine Awarded to Pioneer Researcher in Synthetic Biology – Newswise

Newswise PITTSBURGH, Oct. 26, 2020 James J. Collins, Ph.D., an innovator in synthetic biology whose ideas have contributed to novel diagnostics and treatments targeting infections and complex diseases, has been awarded the 2020 Dickson Prize in Medicine, the University of Pittsburgh School of Medicines highest honor.

The prize is given annually to an American biomedical researcher who has made significant, progressive contributions to medicine. The award consists of a specially commissioned medal, a $50,000 honorarium and an invitation to present the keynote lecture during the Universitys annual campus-wide showcase of scientific research. Due to the COVID-19 pandemic, both the annual showcase and Collins lecture have been postponed until 2021 at a date to be determined.

Dr. Collins is defining whats possible in the disciplines of synthetic and systems biology. His highly creative work applying engineering design principles to molecular biology has generated numerous new diagnostics and therapeutics with wide application to medicine, said Anantha Shekhar, M.D., Ph.D., Pitts senior vice chancellor for the health sciences and John and Gertrude Petersen Dean of Medicine. It is our honor to recognize him with the School of Medicines most prestigious award.

Im grateful to work with outstanding lab members and collaborators whose dedication and insight have been critical to what weve achieved, said Collins, who is the Termeer Professor of Medical Engineering and Science in the Department of Biological Engineering at Massachusetts Institute of Technology and is affiliated faculty with the Broad Institute of MIT and Harvard University, and the Wyss Institute at Harvard. I am thrilled and honored to receive the Dickson Prize in Medicine.

A seminal 2000 publication describing the successful creation of a stable, synthetic gene circuit in Escherichia coli bacteria has been cited more than 4,000 times and marked the arrival of an important new discipline in biomedicine. Collins later demonstrated that synthetic gene networks could be linked with a cells genetic circuitry as a regulatory mechanism to create programmable cells for biomedical applications.

More recently, Collins has created engineered microbes and whole-cell biosensors to serve as in vivo diagnostics and therapeutics. One innovative platform that he and colleagues developed embeds freeze-dried, cell-free synthetic gene networks onto paper and other materials with a wide range of potential clinical and research applications.

The resulting materials contain properties of a living cell, are stable at room temperature and can be activated by simply adding water. Collinss work on freeze-dried, cell-free synthetic biology has established a platform for a new class of rapid, programmable in vitro diagnostics for emerging pathogens, including drug-resistant bacteria and viruses. Collins and his team currently are developing a rapid self-activating COVID-19 face mask as a wearable diagnostic.

Collins earned an A.B. in physics at the College of the Holy Cross in Worcester, Mass., before completing a Ph.D. in medical engineering at the University of Oxford with the distinction of Rhodes Scholar. He has received a MacArthur Foundation Genius award, NIH Directors Pioneer Award and Sanofi-Institut Pasteur Award. Collins is an elected member of the National Academy of Sciences, National Academy of Engineering, National Academy of Medicine and the American Academy of Arts and Sciences. He is a charter fellow of the National Academy of Inventors.

To read this release online or share it, visit http://www.upmc.com/media/news/102620-Dickson-Prize-2020.

Read more from the original source:
2020 Dickson Prize in Medicine Awarded to Pioneer Researcher in Synthetic Biology - Newswise

Insitro and BMS Team Up to Pave the Way for New ALS and FTD Treatments – BioSpace

Insitro founder and CEO Daphne Koller (left) and CFO Mary Rozenman (right). Photo courtesy of Insitro.

San Francisco-based Insitro announced today that it has entered a five-year discovery collaboration agreement with Bristol Myers Squibb to discover and develop novel therapies for the treatment of amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).

Through this collaboration, Insitro will utilize its proprietary platform, Insitro Human (ISH), to create induced pluripotent stem cell (iPSC) derived disease models for both diseases. This platform applies machine learning, human genetics and functional genomics to create predictive in vitro models. ISH can potentially provide insight into how these diseases progress within patients. Bristol Myers Squibb will have the option to select from targets identified by Insitro to advance through clinical development and commercialization.

Neurodegenerative disorders like ALS and FTD have historically been a challenging therapeutic area, with no disease modifying treatments today. We are excited to partner with Bristol Myers Squibb and its world-class neuroscience leaders, who share our vision of leveraging human genetics, machine learning, and high-throughput biology and chemistry in order to identify and provide new treatments for patients suffering from these devastating diseases, said Daphne Koller, founder and chief executive officer of Insitro. Since founding Insitro just over two years ago, we have demonstrated our capabilities in building predictive models to discover novel targets and patient segments. We have also developed new approaches to machine-learning-enabled therapeutics design, which we look forward to deploying to discover treatments for novel targets emerging from this collaboration.

Insitro is set to receive $50 million as an upfront payment, and it will be eligible to receive an additional $20 million in near term operational milestones.

We believe that machine learning and data generated by novel experimental platforms offer the opportunity to rethink how we discover and design novel medicines, said Richard Hargreaves, Ph.D., senior vice president, head of neuroscience TRC research and early development, Bristol Myers Squibb. There is an unmet medical need for therapies to treat ALS and FTD and we are excited by the prospect of working with Insitros team towards our shared goal of identifying transformative treatments for patients with these devastating diseases.

Insitro recently strengthened its machine learning-based drug discovery capabilities through the acquisition of Haystack Sciences back on Oct. 22. Haystack focuses on synthesizing, breeding and analyzing large, diverse combinatorial chemical libraries encoded by unique DNA sequences called DNA-encoded libraries (DELs). Insitro intends on leveraging the DEL technology to collect massive small molecule data.

We are thrilled to have the Haystack team join Insitro, Koller said at the time of the announcement. For the past two years, Insitro has been building a company focused on the creation of predictive cell-based models of disease in order to enable the discovery of novel targets and evaluate the benefits of new or existing molecules in genetically defined patient segments. This acquisition enables us to expand our capabilities to the area of therapeutic design and advances us towards our goal of leveraging machine learning across the entire process of designing and developing better medicines for patients.

Haystacks platform combines several elements, including the capability to synthesize small molecule collections. With these advantages, Insitro will be better equipped to develop multi-dimensional predictive models for small molecule design.

I am excited by the opportunity to join a company with such a uniquely open and collaborative culture and to work with and learn from colleagues in data science, machine learning, automation and cell biology, said Richard E. Watts, co-founder and chief executive officer of Haystack Sciences. The capabilities enabled by joining our efforts are considerably greater than the sum of the parts, and I look forward to helping build core drug discovery efforts at Insitro.

Read this article:
Insitro and BMS Team Up to Pave the Way for New ALS and FTD Treatments - BioSpace

Scientists discover new organic compounds that could have helped form the first cells – Newswise

Newswise Chemists studying how life started often focus on how modern biopolymers like peptides and nucleic acids contributed, but modern biopolymers don't form easily without help from living organisms. A possible solution to this paradox is that life started using different components, and many non-biological chemicals were likely abundant in the environment. A new survey conducted by an international team of chemists from the Earth-Life Science Institute (ELSI) at Tokyo Institute of Technology and other institutes from Malaysia, the Czech Republic, the US and India, has found that a diverse set of such compounds easily form polymers under primitive environmental conditions, and some even spontaneously form cell-like structures.

Understanding how life started on Earth is one of the most challenging questions modern science attempts to explain. Scientists presently study modern organisms and try to see what aspects of their biochemistry are universal, and thus were probably present in the organisms from which they descended. The best guess is that life has thrived on Earth for at least 3.5 billion of Earth's 4.5 billion year history since the planet formed, and most scientists would say life likely began before there is good evidence for its existence. Problematically, since Earth's surface is dynamic, the earliest traces of life on Earth have not been preserved in the geological record. However, the earliest evidence for life on Earth tells us little about what the earliest organisms were made of, or what was going on inside their cells. "There is clearly a lot left to learn from prebiotic chemistry about how life may have arisen," says the study's co-author Jim Cleaves.

A hallmark of life is evolution, and the mechanisms of evolution suggest that common traits can suddenly be displaced by rare and novel mutations which allow mutant organisms to survive better and proliferate, often replacing previously common organisms very rapidly. Paleontological, ecological and laboratory evidence suggests this occurs commonly and quickly. One example is an invasive organism like the dandelion, which was introduced to the Americas from Europe and is now a common weed causing lawn-concerned homeowners to spend countless hours of effort and dollars to eradicate. Another less whimsical example is COVID-19, a virus (technically not living, but technically an organism) which was probably confined to a small population of bats for years, but suddenly spread among humans around the world. Organisms which reproduce faster than their competitors, even only slightly faster, quickly send their competitors to what Leon Trotsky termed the "ash heap of history." As most organisms which have ever existed are extinct, co-author Tony Z. Jia suggests that "to understand how modern biology emerged, it is important to study plausible non-biological chemistries or structures not currently present in modern biology which potentially went extinct as life complexified."

This idea of evolutionary replacement is pushed to an extreme when scientists try to understand the origins of life. All modern organisms have a few core commonalities: all life is cellular, life uses DNA as an information storage molecule, and uses DNA to make ribonucleic RNA as an intermediary way to make proteins. Proteins perform most of the catalysis in modern biochemistry, and they are created using a very nearly universal "code" to make them from RNA. How this code came to be is in itself enigmatic, but these deep questions point to their possibly having been a very murky period in early biological evolution ~ 4 billion years ago during which almost none of the molecular features observed in modern biochemistry were present, and few if any of the ones that were present have been carried forward.

Proteins are linear polymers of amino acids. These floppy strings of polymerised amino acids fold into unique three-dimensional shapes, forming extremely efficient catalysts which foster precise chemical reactions. In principle, many types of polymerised molecules could form similar strings and fold to form similar catalytic shapes, and synthetic chemists have already discovered many examples. "The point of this kind of study is finding functional polymers in plausibly prebiotic systems without the assistance of biology, including grad students," says co-author Irena Mamajanov.

Scientists have found many ways to make biological organic compounds without the intervention of biology, and these mechanisms help explain these compounds' presence in samples like carbonaceous meteorites, which are relics of the early solar system, and which scientists don't think ever hosted life. These primordial meteorite samples also contain many other types of molecules which could have formed complex folded polymers like proteins, which could have helped steer primitive chemistry. Proteins, by virtue of their folding and catalysis mediate much of the complex biochemical evolution observed in living systems. The ELSI team reasoned that alternative polymers could have helped this occur before the coding between DNA and protein evolved. "Perhaps we cannot reverse-engineer the origin of life; it may be more productive to try and build it from scratch, and not necessarily using modern biomolecules. There were large reservoirs of non-biological chemicals that existed on the primeval Earth. How they helped in the formation of life-as-we-know-it is what we are interested in," says co-author Kuhan Chandru.

The ELSI team did something simple yet profound: they took a large set of structurally diverse small organic molecules which could plausibly be made by prebiotic processes and tried to see if they could form polymers when evaporated from dilute solution. To their surprise, they found many of the primitive compounds could, though they also found some of them decomposed rapidly. This simple criterion, whether a compound is able to be dried without decomposing, may have been one of the earliest evolutionary selection pressures for primordial molecules.

The team conducted one further simple test. They took these dried reactions, added water and looked at them under a microscope. To their surprise, some of the products of these reaction formed cell-sized compartments. That simple starting materials containing 10 to 20 atoms can be converted to self-organised cell-like aggregates containing millions of atoms provides startling insight into how simple chemistry may have led to complex chemistry bordering on the kind of complexity associated with living systems, while not using modern biochemicals.

"We didn't test every possible compound, but we tested a lot of possible compounds. The diversity of chemical behaviors we found was surprising, and suggests this kind of small-molecule to functional-aggregate behavior is a common feature of organic chemistry, which may make the origin of life a more common phenomenon than previously thought," concludes co-author Niraja Bapat.

###

Tokyo Institute of Technology (Tokyo Tech)stands at the forefront of research and higher education as the leading university for science and technology in Japan. Tokyo Tech researchers excel in fields ranging from materials science to biology, computer science, and physics. Founded in 1881, Tokyo Tech hosts over 10,000 undergraduate and graduate students per year, who develop into scientific leaders and some of the most sought-after engineers in industry. Embodying the Japanese philosophy of "monotsukuri," meaning "technical ingenuity and innovation," the Tokyo Tech community strives to contribute to society through high-impact research.

The Earth-Life Science Institute (ELSI)is one of Japan's ambitious World Premiere International research centers, whose aim is to achieve progress in broadly inter-disciplinary scientific areas by inspiring the world's greatest minds to come to Japan and collaborate on the most challenging scientific problems. ELSI's primary aim is to address the origin and co-evolution of the Earth and life.

The World Premier International Research Center Initiative (WPI)was launched in 2007 by the Ministry of Education, Culture, Sports, Science and Technology (MEXT) to help build globally visible research centers in Japan. These institutes promote high research standards and outstanding research environments that attract frontline researchers from around the world. These centers are highly autonomous, allowing them to revolutionise conventional modes of research operation and administration in Japan.

Continued here:
Scientists discover new organic compounds that could have helped form the first cells - Newswise

Bill Gates-Backed Ginkgo Bioworks Has A New $40 Million Spinout Using Synthetic Biology To Clean Wastewater – Forbes

Nicole Richards, CEO of Allonnia.

Nature has a remarkable ability to recycle. It can break apart complex organic materials into simpler compounds. Then nature will re-use those substances to build plants and animals.

Last week, Allonnia launched with $40 million in funding to engineer and commercialize microbes to eliminate pollutants in wastewater and soil.

"The waste problem is vast and growing, and impacts the health of our planet and everyone," said Nicole Richards who joined Allonnia as CEO after a stint at Dupont. "Luckily, nature already uses microbes to break down waste. Allonnia will be accelerating and scaling natural processes to develop new breakthroughs and increase the efficiency of waste remediation."

Allonnia is the third company to launch out of the Ferment Consortium, Ginkgo Bioworks' $350 million investment vehicle leveraging biology to solve global challenges and transform established industries. Ferment Consortium companies Joyn Bio, Motif Foodworks, and now Allonnia will utilize Ginkgo's foundry for biological engineering, its iterative codebase model, and an extensive industry network of partners and investors.

The company is also backed by Bill Gates' Cascade Investments, Battelle, General Atlantic, and Viking Global Investors.

Manufacturers have started looking at their waste streams differently. The business community has learned that reducing waste - including toxic waste - often means less cost. Reducing waste could also increase efficiencies and boost profits. Taking a cue from nature - where there is no waste - manufacturers are beginning to look at their waste streams as potential assets.

The potential to treat industrial wastewater and land treatment, improve oil and gas processing, impact plastics degradation, and recycle consumer goods is worth hundreds of billions of dollars globally. Richards, who last served as growth, strategy, and M&A director of Water Solutions at Dupont, saw an opportunity.

"Waste pollution is one of the most pivotal environmental issues impacting public and planetary health. Traditional solutions have reached their limit," continued Richards. "Microbes' ability to break down substances have always made them appealing for waste remediation. Our job at Allonnia will be to accelerate and scale the natural process of breaking down waste while increasing efficiency and sustainability."

Allonnia targets a class of man-made chemicals known as PFAs, which are found in a wide range of consumer products that people use daily including food packaging, non-stick pots and pans, and water repellent fabrics. Some of the most commonly used PFAs have long lives, earning the name "the forever chemicals."

Allonnia aims to change the current trajectory of waste management, by leveraging Ginkgo's platform and recent advances in protein engineering and cell design to develop microbial and enzymatic solutions that destroy environmental contaminants. Allonnia also aims to recover and upcycle critical elements found in waste streams such as manufacturing waste, catalyst recovery, and electronic components. Many of these materials are difficult to mine and costly to recycle using traditional methods. Allonnia will design biological processes to specifically and selectively recover valuable elements in complex waste streams to make them reusable for future manufacturing processes.

Richards believes Allonia has the opportunity to change how we view waste. "We consider waste to be a failure of the human imagination. Allonnia will bring the power of synthetic biology tools to revolutionize the waste markets and address problems where new approaches are badly needed. Our vision is a waste- and pollution-free world. Our contribution will be mitigating the damage that has been done and helping create a better world for the future."

Im the founder of SynBioBeta, and some of the companies that I write aboutincluding Ginkgo Bioworksare sponsors of the SynBioBeta conference and weekly digest. Thank you to Karl Schmieder for additional research and reporting in this article.

Read more:
Bill Gates-Backed Ginkgo Bioworks Has A New $40 Million Spinout Using Synthetic Biology To Clean Wastewater - Forbes

Meet the First Black Woman to Receive a Ph.D. in Neuroscience from the University of Rochester – Diverse: Issues in Higher Education

October 29, 2020 | :

Coming from an all-girls school in Jamaica to a public school in the United States, Dr. Monique Mendes had to adjust to her classes and American culture.

Despite all the changes, her interest in science never faded. She was always drawn to answering questions through the scientific process.

Mendes decided to pursue a biology degree at the University of Florida. However, while there, she found her passion for neuroscience while working in a lab.

Dr. Monique Mendes

[The lab] is where I had real hands on experiences working on a project from the beginning all the way to the end, says Mendes who earned a Ph.D. from the University of Rochester Medical Centers (URMC) Del Monte Institute for Neuroscience. I had to do all the experiments and I helped with writing the paper. That was where I realized that it was really exciting to be a part of science.

Her desire to pursue a Ph.D. came after she joined the McNair Scholars Program at the University of Florida. The program aims to support undergraduate students from underrepresented and low-income backgrounds. It offers mentorship, financial assistance and other resources to help students prepare for a doctoral degree.

As both a first-generation undergraduate and doctoral student, she relied on mentorship from faculty members.

I definitely had no idea what was going on in the beginning, she says. I was fortunate to have a number of mentors throughout my career that really put my success as a priority. Throughout the years, I gained the experience and the resources I needed to succeed.

At the end of July, Mendes defended her dissertation, The Kinetics of Microglial Ontogeny and Maturation in the Adult Brain.

[The focus] was really to understand how cells renew, how they mature and to do a real time analysis of their dynamic in the brain, she adds.

Upon graduating, Mendes was surprised to learn that she became the first Black woman in URMCs history to receive a Ph.D. in neuroscience.

I felt really incredibly empowered because I felt like I was setting the stage for more Black women to come to Rochester, she says, where they can feel like this is something they can do and something they can be successful at. Hopefully, I showed other women that this was possible.

Due to low representation of Black women within the field, Mendes felt that she never had another student or faculty member look like her in the classroom.

However, after initiatives such as the BlackInNeuro campaign launched on Twitter, she was able to meet more Black females in the field.

I think in the next couple of years, we are going to have a number of Black women in neuroscience, which is going to be fantastic, says Mendes.

To recruit more Black women into the neuroscience field, she recommends that schools or companies create more opportunities for them.

I would say create an environment that is not only diverse but inclusive and also paying attention to the cultures so that Black women can feel that this is a place for them, says Mendes. There is a seat at the table. I just think thats probably the most important thing.

Her accolades include being appointed as a fellow of the Neuroscience Scholars Program by the Society for Neuroscience and receiving the Edward Peck Curtis Award for Excellence in Teaching by a Graduate Student.

Additionally, Mendes became the first URMC graduate student to receive the F99/K00 NIH Blueprint Diversity Specialized Predoctoral to Postdoctoral Advancement in Neuroscience fellowship from the National Institute of Neurological Disorders in Stroke.

She recently began her post-doctoral fellowship at Stanford University in the lab of researcher Dr. Mark Schnitzer. There, she will focus on how glia cells impact memory and learning.

Mendes plans to transition to a faculty position at a research-intensive institution as well as become an advocate and mentor for students.

Outside of the science field, she plays violin and plans to join a community orchestra. Mendes musical interest stemmed from her time in Jamaica she began playing violin at the Immaculate Conception High School in Jamaica. Since then, she has played at weddings as well as for the Florida Youth Orchestra, the Brighton Symphony Orchestra and the Rochester Philharmonic Orchestra here in the United States.

It is a sense of community, says Mendes. It is nice to have something outside of science to relax. Surprisingly, orchestra is relaxing for me. People would think otherwise. But it feels good to have like a cohort of people that you can talk about something that you are all passionate about. I have had a lot of fun over the years.

This article originally appeared in the October 29, 2020 edition of Diverse. You can find it here.

Read more:
Meet the First Black Woman to Receive a Ph.D. in Neuroscience from the University of Rochester - Diverse: Issues in Higher Education

Neuroscience Market Outlook and Opportunities in Grooming Regions 2027 – re:Jerusalem

CMI published a business research report on Neuroscience Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecasts 20202026. Neuroscience Market with 150+ market data Tables, Pie Chat, Graphs & Figures spread through Pages and easy to understand detailed analysis. The information is gathered based on modern floats and requests identified with the administrations and items.

The global Neuroscience Market analysis further provides pioneering landscape of market along with market augmentation history and key development involved in the industry. The report also features comprehensive research study for high growth potential industries professional survey with market analysis. Neuroscience Market report helps the companies to understand the market trends and future market prospective,opportunities and articulate the critical business strategies.

Get Free PDF Research Report Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/2487

Geographical segmentation of Neuroscience Market involves the regional outlook which further covers United States, China, Europe, Japan, Southeast Asia and Middle East & Africa. This report categorizes the market based on manufacturers, regions, type and application.

Neuroscience Market: Competitive Landscape

Leading players operating in the global Neuroscience Market include:Alpha Omega, Inc., GE Healthcare, Axion Biosystems, Inc., Siemens Healthineers, Blackrock Microsystems LLC, Femtonics Ltd., Intan Technologies, LaVision Biotec GmbH, Mediso Medical Imaging Systems, Neuralynx Inc., NeuroNexus Technologies, Inc., Newport Corporation, Plexon Inc., Noldus Information Technology, Scientifica Ltd., Sutter Instrument Corporation, Thomas Recording GmbH, and Trifoil Imaging Inc.

Scope of the Report

The key features of the Neuroscience Market report 2020-2026 are the organization, extensive amount of analysis and data from previous and current years as well as forecast data for the next five years. Most of the report is made up from tables, charts and figures that give our clients a clear picture of the Neuroscience Market. The structure of Neuroscience Market by identifying its various segments and sub-segments to help understanding the report.

Neuroscience Market Research Report gives current competitive analysis and also valuable insights to clients/industries, which will assist them to prepare a new strategy to expand or penetrate in a global Neuroscience Market.

As the report proceeds further, it covers the analysis of key market participants paired with development plans and policies, production techniques, price structure of the Neuroscience Market. The report also identifies the other essential elements such as product overview, supply chain relationship, raw material supply and demand statistics, expected developments, profit and consumption ratio.

Important Neuroscience Market Data Available In This Report:

Receive FREE Sample of Research Report @ https://www.coherentmarketinsights.com/insight/request-sample/2487

An Overview of the Impact of COVID-19 on this Market:

The pandemic of COVID-19 continues to expand and impact over 175 countries and territories. Although the outbreak appears to have slowed in China, COVID-19 has impacted globally. The pandemic could affect three main aspects of the global economy: production, supply chain, and firms and financial markets. National governments have announced largely uncoordinated, country-specific responses to the virus. As authorities encourage social distancing and consumers stay indoors, several businesses are hit. However, coherent, coordinated, and credible policy responses are expected to offer the best chance at limiting the economic fallout.

National governments and international bodies are focused on adopting collaborative efforts to encourage financial institutions to meet the financial needs of customers and members affected by the coronavirus. However, there are some sectors that have remained unscathed from the impact of the pandemic and there are some that are hit the hardest.

We, at Coherent Market Insights, understand the economic impact on various sectors and markets. Using our holistic market research methodology, we are focused on aiding your business sustain and grow during COVID-19 pandemics. With deep expertise across various industries-no matter how large or small- and with a team of highly experienced and dedicated analysts, Coherent Market Insights will offer you an impact analysis of coronavirus outbreak across industries to help you prepare for the future.

Interested about who is winning the race of COVID-19 Vaccine. Coherent Market Insights (CMI)provides COVID-19 Vaccine Tracker for all the latest updates about COVID-19 Vaccine.

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:

Name: Mr. ShahPhone: US +12067016702 / UK +4402081334027Email: sales@coherentmarketinsights.com

Continue reading here:
Neuroscience Market Outlook and Opportunities in Grooming Regions 2027 - re:Jerusalem

Seemingly Healthy College Student: I Didn’t Think It Could be a Stroke (But It Was) – Baptist Health South Florida

Canon McClure, 20, a junior at the University of Miami, woke up one day in August after an intense headache the previous day. Over the course of the new day, however, she realized something was very wrong. She felt some weakness on her right side and it became increasingly difficult for her to communicate with people.

Without any underlying health condition or any family medical history of concern, Ms. McClure was suffering the beginning of an ischemic stroke caused by a sizeable clot in her middle cerebral artery (MCA), as the stroke response team at Baptist Hospitals Miami Neuroscience Institute would soon diagnose.

(Watch now: Hear from stroke patient Cannon McClure as she shares her stroke recovery story, along with Italo Linfante, M.D., medical director of Neuroendovascular Surgery at Miami Neuroscience Institute and Miami Cardiac & Vascular Institute, and Kevin Abrams, M.D., chair division of Neuroradiology at Miami Neuroscience Institute. Video by Steve Pipho.)

She is majoring in vocal performance with a focus on classical music and opera.

I definitely knew that something was seriously wrong, but I didnt really consider that it might have been a stroke, recalls the UM student from Plano, Texas, who is majoring in vocal performance with a focus on classical music and opera. I just didnt think that strokes really happened to people my age and theres nothing in my family history of heart attack or stroke or blood clotting or anything.

This was Very Urgent

Initially,Ms. McClure was transported to nearby Doctors Hospital, part of Baptist HealthSouth Florida. But after an ER physician consulted with Kevin Abrams, M.D., chair division of Neuroradiology atMiami Neuroscience Institute, she was transported to BaptistHospital, where the Baptist Emergency Stroke Team (B.E.S.T.) took quick action.

This was, obviously, very urgent, said Dr. Abrams. She was in the early stages of an acute ischemic attack (the most common type of stroke). I saw that she was 20-years-old and didnt have that many severe symptoms, and the symptoms were from yesterday. I was concerned that she could fall through the cracks because she didnt look as bad as the CT scan showed.

Ms. McClureremembers a whole team of people waiting for her at BaptistHospital. Also anticipating her arrival was Italo Linfante, M.D., medical director ofNeuroendovascular Surgery at Miami Neuroscience Institute and Miami Cardiac & VascularInstitute.

Theystarted asking me questions: date of birth, emergency contacts, that kind ofthing, she said. And then we got to the outside the room where theywere going to do the procedure, and Dr. Linfante started talking to me abouthow they were going to get the clot out of my brain.

Dr. Linfantewas ready to perform a life-saving thrombectomy, a procedure during which acatheter is threaded into an artery and up through the neck until it reachesthe blood clot causing the stroke.

At that time, her brain was compensating very well for the lack of blood flow. Therefore, she did not have a severe neurological deficit. However, given the size of the blood clot and the location of the occlusion, if we would have not open the artery to restore normal blood flow, these patients worsen and can be left with severe disability or death, said Dr. Linfante. We were able to go up into the middle cerebral artery of the brain and able to remove the clot, which was actually very dense and well-constructed and therefore it would have not dissolved spontaneously without our intervention.

Cannon McClure with her parents.

Before the procedure, Dr. Linfante called up Ms. McClures parents, who live Texas. Dr. Linfante talked to my parents and the nurses talked to them. And they were able to make them feel a little bit reassured about what was going to happen to me, says Ms. McClure.

Back to Doing All of the Things I Did Before

Ms. McClurerecalls feeling better with her ability to communicate fully restored soonafter the procedure, which takes less than 30 minutes.

It wasbasically just a matter of the anesthesia completely wearing off and I was backto almost my normal self, she said. It took about a week or two,but eventually all the sensation came back to my right side. Now, Im able todo all of the things that I did before.

Dr. Abrams said Dr. Linfante sent him a screenshot of the large clot he extracted from her left middle cerebral artery. And he said that she was doing great and I couldnt have been happier, said Dr. Abrams. It really made my day. Shes 20 years old and I have two children that are about that age and are also in college. So, it really hit home for me.

Hole inthe Heart: Stroke Mystery Likely Solved

But how canan otherwise healthy 20-year-old suffer a stroke? After Ms. McClure underwentall her tests and screenings, that mystery was likely solved, explains Dr.Linfante. Ms. McClure was born with what is commonly known as a hole inthe heart. Medically speaking its a patent foramen ovale, or PFO,essentially a hole in the wall of tissue (septum) between the left and rightupper chambers of the heart.

At birth,the foramen ovale usually closes, and within a few months, it seals completelyin about 75 percent of births. When it remains open, it is called a PFO. Forthe vast majority of the millions of people with a PFO, it is not a problem,even though blood is leaking from the right atrium to the left. Problems canarise when that blood contains a clot, as in the case of what likely happenedto Ms. McClure, says Dr. Linfante.

Ms. McClure recently underwent a successful, minimally invasive procedure by interventional cardiologist Bernardo Lopez-Sanabria, M.D., at Miami Cardiac & Vascular Institute, to close the PFO.

I haveto take an aspirin every day (because of the stroke) just as a preventativemeasure, says Ms. McClure. They did say that closing the PFOgreatly reduces my risk of ever having a stroke again. So thats really reassuringbecause if you have a stroke, its more likely that youll have oneagain.

Tags: Miami Neuroscience Institute, stroke

See more here:
Seemingly Healthy College Student: I Didn't Think It Could be a Stroke (But It Was) - Baptist Health South Florida